Plasmodium fakiparum In Vitro Resistance to Monodesethylamodiaquine, Dakar, Senegal, 2014

Bécaye Fall (1) , Marylin Madamet (2) , Cheikhou Camara (3) , Rémy Amalvict (4, 5, 6) , Mansour Fall (7) , Aminata Nakoulima (8) , Bakary Diatta (7) , Yaya Diemé (1) , Boubacar Wade (9) , Bruno Pradines (5, 2)

1 Laboratoire d'étude de la chimiosensibilité du paludisme
2 IRBA - Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge]
3 Service des Urgences
4 IP-TPT - Infections Parasitaires : Transmission, Physiopathologie et Thérapeutiques
5 URMITE - Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes
6 Unité de Parasitologie
7 Service de Réanimation Médicale
8 Service de pédiatrie
9 Chefferie

We successfully cultured 36 Plasmodium falciparum isolates from blood samples of 44 malaria patients admitted to the Hopital Principal de Dakar (Dakar, Senegal) during August December 2014. The prevalence of isolates with in vitro reduced susceptibility was 30.6% for monodesethylamodiaquine, 52.8% for chloroquine, 44.1% for mefloquine, 16.7% for doxycycline, 11.8% for piperaquine, 8.3% for artesunate, 5.9% for pyronaridine, 2.8% for quinine and dihydroartemisinin, and 0.0% for lumefantrine. The prevalence of isolates with reduced in vitro susceptibility to the artemisinin-based combination therapy partner monodesethylamodiaquine increased from 5.6% in 2013 to 30.6% in 2014. Because of the increased prevalence of P. falciparum parasites with impaired in vitro susceptibility to monodesethylamodiaquine, the implementation of in vitro and in vivo surveillance of all artemisinin-based combination therapy partners is warranted.

Domaines: Maladies infectieuses; Parasitologie; Pharmacologie

Bécaye Fall, Marylin Madamet, Cheikhou Camara, Rémy Amalvict, Mansour Fall, et al.. Plasmodium fakiparum In Vitro Resistance to Monodesethylamodiaquine, Dakar, Senegal, 2014. Emerging Infectious Diseases, 2016, 22 (5), pp.841-845. ⟨10.3201/eid2205.151321⟩. ⟨hal-01458381⟩